Oncolytic virotherapy: a potential therapeutic approach for cholesteatoma

被引：1
|
作者：
Lipschitz, Noga [1 ]
Earl, Brian R. [1 ,2 ]
Cripe, Timothy P. [3 ,4 ]
Samy, Ravi N. [1 ,5 ,6 ]
机构：
[1] Univ Cincinnati, Coll Med, Dept Otolaryngol Head & Neck Surg, Cincinnati, OH USA
[2] Univ Cincinnati, Dept Commun Sci & Disorders, Coll Allied Hlth Sci, Cincinnati, OH USA
[3] Nationwide Childrens Hosp, Dept Pediat, Div Hematol Oncol Blood & Marrow Transplant, Columbus, OH USA
[4] Nationwide Childrens Hosp, Ctr Childhood Canc & Blood Dis, Res Inst, Columbus, OH USA
[5] Univ Cincinnati, Neurosensory Disorders Ctr, Gardner Neurosci Inst, 213 Albert Sabin Way,MSB 6407, Cincinnati, OH 45267 USA
[6] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA
来源：
CURRENT OPINION IN OTOLARYNGOLOGY & HEAD AND NECK SURGERY | 2020年 / 28卷 / 05期
关键词：
cholesteatoma; herpes simplex virus; oncolytic virotherapy; TALIMOGENE LAHERPAREPVEC; ACQUIRED CHOLESTEATOMA; VIRUS; SAFETY; ADENOVIRUS; MELANOMA; EFFICACY; PATHOGENESIS; COMBINATION; HSV-1;
D O I：
10.1097/MOO.0000000000000651
中图分类号：
R76 [耳鼻咽喉科学];
学科分类号：
100213 ;
摘要：
Purpose of review To review the principles of oncolytic virotherapy and summarize the recent preliminary evidence on the efficacy of oncolytic virotherapy for cholesteatoma (CHST) treatmentin vitroin human CHST cells and in a gerbil CHST model. Recent findings The use of oncolytic virotherapy for nonmalignant lesions is innovative. In-vitro results showed that oncolytic herpes simplex virus 1 (oHSV) selectively targets and kills CHST cells. In a gerbil model of CHST, local oHSV injections were associated with a decrease in CHST volume and modulation of bony changes. Surgical treatment options for CHST are limited by high morbidity and recidivism, emphasizing the need for developing treatment alternatives. Preliminary results support the potential therapeutic effect of oncolytic virotherapy on CHST, yet further research is needed to evaluate this novel approach.
引用
收藏
页码：281 / 285
页数：5
相关论文
共 50 条
  • [31] Caprine herpesvirus 1 (CpHV-1) as a potential candidate for oncolytic virotherapy
    Montagnaro, Serena
    Damiano, Sara
    Ciarcia, Roberto
    Puzio, Maria Valeria
    Ferrara, Gianmarco
    Iovane, Valentina
    Forte, Iris Maria
    Giordano, Antonio
    Pagnini, Ugo
    CANCER BIOLOGY & THERAPY, 2019, 20 (01) : 42 - 51
  • [32] Optimizing oncolytic virotherapy in cancer treatment
    Harrington, Kevin
    Freeman, Daniel J.
    Kelly, Beth
    Harper, James
    Soria, Jean-Charles
    NATURE REVIEWS DRUG DISCOVERY, 2019, 18 (09) : 689 - 706
  • [33] Oncolytic Virotherapy of Canine and Feline Cancer
    Gentschev, Ivaylo
    Patil, Sandeep S.
    Petrov, Ivan
    Cappello, Joseph
    Adelfinger, Marion
    Szalay, Aladar A.
    VIRUSES-BASEL, 2014, 6 (05): : 2122 - 2137
  • [34] Potentiation of oncolytic virotherapy with armed shRNA
    Guo, Wei
    Fang, Bingliang
    CANCER BIOLOGY & THERAPY, 2009, 8 (01) : 92 - 93
  • [35] Cytokines in oncolytic virotherapy
    Pol, Jonathan G.
    Workenhe, Samuel T.
    Konda, Prathyusha
    Gujar, Shashi
    Kroemer, Guido
    CYTOKINE & GROWTH FACTOR REVIEWS, 2020, 56 : 4 - 27
  • [36] What is oncolytic virotherapy?
    Cockle, Julia V.
    Scott, Karen J.
    ARCHIVES OF DISEASE IN CHILDHOOD-EDUCATION AND PRACTICE EDITION, 2018, 103 (01): : 43 - 45
  • [37] A Multiscale Mathematical Model for Oncolytic Virotherapy
    Paiva, Leticia R.
    Binny, Christopher
    Ferreira, Silvio C., Jr.
    Martins, Marcelo L.
    CANCER RESEARCH, 2009, 69 (03) : 1205 - 1211
  • [38] The Multifaceted Role of Macrophages in Oncolytic Virotherapy
    Hofman, Laura
    Lawler, Sean E.
    Lamfers, Martine L. M.
    VIRUSES-BASEL, 2021, 13 (08):
  • [39] Poxvirus oncolytic virotherapy
    Torres-Dominguez, Lino E.
    McFadden, Grant
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2019, 19 (06) : 561 - 573
  • [40] Lung cancer and oncolytic virotherapy--enemy's enemy
    Li, Zhang
    Feiyue, Zhang
    Gaofeng, Li
    Haifeng, Liang
    TRANSLATIONAL ONCOLOGY, 2023, 27
12345